about qualitative analysis of CD34 ϩ cell subsets. However, what is the clinical relevance of such a comparison? The authors show no difference between the two G-CSFs except that granocyte may be more efficient at expanding and mobilizing CD34 ϩ /CD19 ϩ cells. However, the difference is most probably due to previous treatment by cyclophosphamide which is known to decrease CD19 ϩ subsets. Since the proportion of patients having received cyclophosphamide is not known in the small studied population (eight in the granocyte group and 11 in the Neupogen group), this creates again some doubt against the validity of this result.
In conclusion, this study based on small, non-homogeneous diagnostic groups of patients with a non-randomized, non-stratified and non-cross-over design, is misleading and neither confirms nor refutes the results of previously published randomized studies by Höglund et al 4 and Watts et al 5 which showed significant differences in efficacy between glycosylated and non-glycosylated rhG-CSF (namely granocyte and neupogen) at priming progenitor cells on a per g basis.
We hope to read soon in the full-paper section of Bone Marrow Transplantation the results of another welldesigned randomized comparative study, aimed at confirming or refuting the previously published study results of Höglund et al 4 and Watts et al 5 which, in contrast to the non-randomized and non-convincing study by Saccardi et al 6 mentioned in Schiodt's paper, have been published in international peer-reviewed journals.
Response to the comment on 'Flow cytometry comparison of CD34
؉ subsets in bone marrow and peripheral blood after priming with glycosylated or nonglycosylated rhG-CSF' by JM Miclea
The criticism raised by Miclea 1 regarding the design of the study is well taken and we agree that the optimal design would have been a large, double-blind, randomised study concerning a single disease, followed by another study of another disease and so forth. As clinicians, however, it may be necessary to make exploratory studies in order to avoid spending valuable research grants and time on welldesigned studies of limited clinical significance. We believe that this is possible wihout producing misleading information when interpreted with care. Evaluated together with other studies, it may provide sufficient information for the decision to initiate a more extensive, randomised study or not. This was the background for the pilot study 2 based on our hypothesis that qualitative differences after priming with glycosylated rhG-CSF, identified by subset numbers in the mobilised stem cells, should be present in all analysed samples. This was not found and we chose to show these results. However, given the opportunity we would now like to show some additional endpoints analysed (Table 1) . Some of the patient characteristics are given as well in
JM Miclea
Institut order to justify the comparison between the two groups (Table 2) . In clinical practice, however, the important question is perhaps not so much the exact number of CD34 ϩ cells that one can mobilise in the individual patient by the use of a certain growth factor as much as the growth factor's ability to mobilise a sufficient number of stem cells in any patient to achieve a safe autograft by leukapheresis. Our impression after conducting this pilot study is that both the G-CSFs used are excellent for this purpose and that they seem to be equally efficient in equal doses. Still, we do not know if a smaller dose of glycosylated G-CSF is equal to 10 g/kg non-glycosylated G-CSF. We would like to emphasise that this issue was addressed in patients with breast cancer, in a prospective and randomised study, published as a full length article.
3 The conclusions drawn from this study were similar to ours, although bio-equivalent doses were used (mean 8.4 g/kg non-glycosylated vs 6.4 g/kg glycosylated rhG-CSF) according to the WHO international potency standard for G-CSF. 4 Even the total costs in the two groups were not different in this study.
As a conclusion, we still do not find reason to conduct further randomised trials, but it is of course open to anyone who may feel the need to do so.
We regret that a typographical error in the manuscript has escaped our notice. We appreciate Miclea's efforts in
Post-transplant Epstein-Barr virus-associated meningoencephalitis and lymphoid interstitial pneumonitis
Post-transplant-associated Epstein-Barr virus (EBV) disease following allogeneic BMT usually presents as masses secondary to B cell proliferation. [1] [2] [3] [4] We present a case of a 4-year-old female, who, following a BMT for AML using an HLA-matched, unrelated donor, T cell-replete donor graft, developed meningoencephalitis and lymphoid interstitial pneumonitis (LIP) associated with EBV.
Pre-transplant serology showed the patient to be EBV seronegative. The clinical course was unremarkable until day +50 post BMT when she acutely developed lethargy, severe ataxia and truncal weakness. She was afebrile, and had no appreciable hepatosplenomegaly or adenopathy. The CsA level was 2688 g/l (whole blood, polyclonal antibody method) and CsA was discontinued. An MRI scan of the brain demonstrated patchy meningeal enhancement, diffuse cerebral atrophy and basal ganglia gliosis. Blood, urine and cerebral spinal fluid (CSF) cultures were negative. The CSF showed 2 RBC and 9 WBC (100% lymphocytes and monocytes). PCR of the CSF and peripheral blood were positive for EBV. CT scans of the chest and abdomen revealed no abnormalities in the abdomen. Although she had no respiratory symptoms or oxygen requirement diffuse bilateral interstitial infiltrates consistent with lymphoid interstitial pneumonitis (LIP) were found on the chest CT scan. In addition to discontinuation of the CsA, interferon-␣ (IFN) at 10 x 10 6 U/m 2 subcutaneously was initiated, as discovering this error. The P value given on page 1167, first column, line three from the bottom: P = 0.46 should read P = 0.15. This error does not affect the conclusions of the study. well as intravenous acyclovir (ACV) (1500 mg/m 2 /day) and IVIG (500 mg/kg/week).
I Schiodt
IFN levels in serum and CSF were determined by an ELISA kit (BioSource International, Camarillo, CA, USA) as per manufacturer's protocol (sensitivity 25 pg/ml and range 0-500 pg/ml). EBV DNA levels in the peripheral blood were semi-quantitated by PCR, as previously described (sensitivity у2 copies/g of DNA). 5, 6 At presentation, EBV was detectable in the CSF (quantitation of EBV levels in the CSF was not performed due to small amounts of DNA) and the level of EBV DNA in peripheral blood was 80 copies. Two weeks after presentation, there was no change in neurologic status, and the CSF remained positive for EBV. However, a repeat chest CT scan showed resolution of the LIP, with a drop to three copies of EBV DNA in the peripheral blood. IFN levels were readily detectable in the serum (252 pg/ml), but IFN was not detectable in the CSF. The IFN dose was then decreased to 3 ϫ 10 6 U/m 2 /day. One month after presentation no objective clinical improvement was appreciated and an MRI scan showed progressive cerebral atrophy, but PCR of the CSF revealed no detectable EBV DNA. The level of IFN in the serum was 114 pg/ml, but again no IFN was detected in the CSF. Over the next few weeks, the patient began to demonstrate increased truncal tone and decreased ataxia. At 3 months following diagnosis of EBV disease, the IFN was discontinued due to liver toxicity, but she continued on ACV (500 mg/m
